Feb 7th 2011. A new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA® (sitagliptin), with extended-release metformin has been approved by the FDA.  The combination of both active substances provides greater A1C goal attainment compared to sitagliptin or metformin alone